Inactive Instrument

Highlights Sio Gene Therapies Deutsche Boerse AG

Equities

6YY

US8293991043

Highlights

Unlock all the news: Be the first to know and act before the market!

Sio Gene Therapies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/23/14	CI
Sio Gene Therapies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	10/22/10	CI
Sio Gene Therapies Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	11/22/11	CI
Sio Gene Therapies Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	14/22/14	CI
Sio Gene Therapies Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	14/22/14	CI
Sio Gene Therapies to Explore and Review A Range of Strategic Alternatives Focused on Maximizing Stockholder Value	27/22/27	CI
Sio Gene Therapies Receives Nasdaq Listing Noncompliance Notice Over Minimum Closing Price	19/22/19	MT
Sio Gene Therapies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	11/22/11	CI
Sio Gene Therapies Inc. Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis	01/22/01	CI
Sio Gene Therapies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	12/21/12	CI
Sio Gene Therapies Announces Successful Manufacture of Three GMP Batches of AXO-Lenti-PD Gene Therapy for Parkinson?s Disease	11/21/11	CI
Sio Gene Receives US Food and Drug Administration's Fast Track Designation for GM2 Gangliosidosis Gene Therapy	01/21/01	MT
Sio Gene Therapies Inc. Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM2 Gene Therapy in Patients with Gm2 Gangliosidosis	01/21/01	CI
Sio Gene Therapies : Secures FDA Fast Track Designation for Gene Therapy Candidate for GM1 Gangliosidosis	21/21/21	MT
Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM1 (AAV9-GLB1) Gene Therapy in Patients with GM1 Gangliosidosis	21/21/21	CI
Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-AAV-GM1 Gene Therapy in GM1 Gangliosidosis	21/21/21	CI
Sio Gene Therapies Announces Dosing of First GM1 Gangliosidosis Early Infantile (Type I) Patient in Ongoing Phase 1/2 Study of AXO-AAV-GM1 Gene Therapy	09/21/09	CI
Sio Gene Therapies Inc. Reports Earnings Results for the First Quarter Ended June 30, 2021	12/21/12	CI
Montes Archimedes Acquisition : Biotech firm Roivant Sciences to go public via $7.3 bln SPAC deal	03/21/03	RE
Angelini Acraf S.p.A. completed the acquisition of Arvelle Therapeutics GmbH from a group of investors for approximately $960 million.	02/21/02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sio Gene Therapies Deutsche Boerse AG

Equities

6YY

US8293991043

Highlights

Filters